Cargando…
The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX(®) Recurrence Score in ER-Positive Invasive Breast Cancers
We assessed mRNA and protein expression levels of the ZN217 oncogene in 17 clinical FFPE ER-positive invasive breast cancer specimens with known (low or high) Oncotype DX(®) Recurrence Scores. This study shows that mRNA or nuclear protein levels of the ZNF217 significantly correlate with Oncotype DX...
Autores principales: | Cohen, Pascale A., Loudig, Olivier, Liu, Christina, Albanese, Joseph, Fineberg, Susan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6546897/ https://www.ncbi.nlm.nih.gov/pubmed/31191299 http://dx.doi.org/10.3389/fphar.2019.00524 |
Ejemplares similares
-
MiRNA expression deregulation correlates with the Oncotype DX(®) DCIS score
por: Loudig, Olivier, et al.
Publicado: (2022) -
Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022) -
The analytical validation of the Oncotype DX Recurrence Score assay
por: Baehner, Frederick L
Publicado: (2016) -
Evaluating ZNF217 mRNA Expression Levels as a Predictor of Response to Endocrine Therapy in ER+ Breast Cancer
por: Vendrell, Julie A., et al.
Publicado: (2019) -
Utilization of Oncotype DX in an Inner City Population: Race or Place?
por: Guth, Amber A., et al.
Publicado: (2013)